Located in Pittsburgh, Pennsylvania, UPMC is an over 8,000 bed, not-for-profit health system that includes 40 hospitals.
“The results from the T2Bacteria pivotal clinical trial were impressive, demonstrating excellent performance and advantages over blood culture,” said Minh-Hong Nguyen, MD, director, Antimicrobial Management Program and director, Transplant Infectious Diseases, UPMC. “T2Bacteria’s detection of bloodstream infections and fast species identification at high sensitivity will expedite life-saving interventions such as the targeting of therapy within hours of blood draw.” 1
“I was pleased to see that T2Candida has become a standard during any discussion regarding rapid diagnostics and antimicrobial stewardship,” said Dr. Clancy. “I believe that the hospitals using it are seeing strong value for their patients as well as better management of the drugs that lead to high resistance and costs.” 2
MICU pilot program: Led to 47% reduction in antifungal expenditure; Median days of therapy pre-intervention vs. post-intervention: 26 days vs. 15.5 days (p=0.005)
T2Bacteria: Covers 71% of Gram-negative bacteria at hospital presentation and detects >50% of all BSI
1. Nguyen, MH, T2 Biosystems Press Release, 2018
2. Clancy, N, T2 Biosystems Press Release, 2017
3. Shields R, et al. Poster Presentation, IDWeek, 2018
Located in Detroit, Michigan, Henry Ford Health System is an over 2,300-bed, not-for-profit hospital system.
“This technology has shown it can expedite the detection of candidemia. As a result, patients receive more prompt and appropriate antifungal therapy.” – Rachel Kenney, PharmD, Henry Ford study co-author
Faster Targeted Therapy: The median time to appropriate antifungal therapy was reduced from 39 hours to 22 hours (P=0.003)
Patients tested with the T2Candida were appropriately treated in a median of 5 hours, compared to 44 hours with blood culture1
Reduced Length of Stay: Henry Ford reported a reduced median ICU length of stay by 7 days and an overall 4 day reduction1
Improved Patient Outcomes: Reduction in occurrence of ocular candidiasis cases were (P<0.28)
1. Wilson N, et al. Journal of Antimicrobial Stewardship, 2017
Located in Fort Myers, Florida, Lee Health is the largest healthcare system in Southwest Florida consisting of four acute care and two specialty hospitals and over 1,400 beds.
“This data demonstrates that innovation at Lee Health is leading to improved care for our patients and also reducing costs,” said John Armistead, Lee Health System Director Pharmacy. “The testing is helping to get our patients suspected of sepsis on the right therapy faster.” 2
Faster Targeted Therapy: T2Candida enabled patients to receive targeted therapy 28 hours faster. Patients suspected of a Candida infection that were tested on the T2Dx received targeted therapy nearly 6 times faster, in only 6 hours compared to conventional practices that took 34 hours.
Improved stewardship and pharmacy savings: The major findings in this study are the decreased time to initiation of targeted antifungal therapy when a T2Candida-directed treatment strategy was employed versus that of a BC-directed therapy approach and the avoidance of empiric therapy in 58.4% (101/173) of T2Candida-negative patients.2
The decreased utilization of empirical micafungin therapy observed in Phase 2 would result in a total savings of $280 per tested patient in antifungal costs alone when compared with historical control data from Phase 1.2
Faster Results: In a separate study the T2Bacteria Panel allowed testing from whole blood samples and provided final results within 4 hours. T2Bacteria Panel provided positive and negative results approximately 20 hours and 122 hours sooner than blood cultures, respectively (p<0.001). T2Bacteria Panel identified all organisms identified by blood cultures of the bacteria included on the panel.3
Stewardship Tool: In the same study a total of 36 opportunities for de-escalation were identified, such a potential to de-escalate coverage for S. aureus and/or P. aeruginosa. The high negative predictive value of the T2Bacteria Panel suggests utility in guiding early antibiotic de-escalation of coverage for organisms not identified.3
1. Lee Health System Press Release, March 28, 2018
2. Patch PM, et al. Journal of Antimicrobial Chemotherapy, 2018
3. Weisz E, et al. White Paper, 2018
Located in Huntsville, Alabama, Huntsville Hospital is a large community and teaching hospital with over 940 beds.1
“With the T2Direct Diagnostics, our hospital is not only reducing the use of antifungal therapy, we’re also identifying far more infected patients than was possible with blood culture,” Dr. Jonathan D. Edwards, Pharm.D., BCPS (AQ-ID), BCGP, Huntsville Hospital1
Proven performance and detection of Candida infections missed by blood culture: The T2Candida® Panel demonstrated overall sensitivity of 94.4% and identified 26 proven infections that were not detected by blood culture.2
Improved stewardship with narrowed, targeted therapy: Negative T2Candida Panel results contributed to the avoidance or de-escalation of antifungal therapy in 64% of these negative patients.
Pharmacy savings: T2 results decreased average duration of therapy of micafungin by 2.1 days.2
1. Edwards J. Oral Presentation, ASM 2017
2. Hassoun A, et al. Utilization of the T2 Candida Panel for rapid Candida species detection in a large community hospital. Poster Presentation, IDWeek 2017
Located in New Brunswick, New Jersey, Robert Wood Johnson Medical School is an over 750 bed, not-for-profit academic medical center.
The T2Direct Diagnostics™ led to reduced use of antifungals and cost savings at Robert Wood Johnson Hospital: Antifungal therapy was avoided or ceased in 67% of patients with a negative T2Candida result and resulted in cost savings due to reduced use of antifungal drugs.2
1. Kirn T. Oral Presentation, ASM Microbe, 2017
2. Bhowmick T, et al. Poster Presentation, ASM Microbe, 2017
Located in Riverside, California, Riverside Community Hospital is an over 470-bed community hospital.
“We are proud to be the first and only acute care hospital in the Inland Empire to invest in this state-of-the-art technology to diagnose sepsis, a very urgent public health issue,” said Patrick Brilliant, president and chief executive officer of Riverside Community Hospital. “We are hopeful that with this technology in our facility, we will see an important change in our ability to diagnose and treat sepsis patients sooner and with the proper medications, ultimately saving lives.”1
Faster Targeted Therapy: 83% of patients who tested positive received appropriate therapy within 6 hours of the blood draw and 100% in under 9 hours. 0 patients who tested positive had been on antifungals prior to testing
Reduced use of unnecessary antifungals: Therapy was discontinued for 100% of the patients who tested negative2